1
Home
Companies

Avenue Therapeutics

Avenue Therapeutics
Leadership team

Dr. Lindsay Allan Rosenwald (Exec. Chairman)

Dr. Xiaoqin Lu M.D. (Consultant)

Dr. Alexandra MacLean M.D. (Chief Exec. Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
0 - 50
Headquarters
New York, New York, United States
Established
2015
Company Registration
SEC CIK number: 0001644963
Traded as
NASDAQ:ATXI
URL
https://www.avenuetx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
History

Avenue Therapeutics was founded in January 2015 to develop and commercialize intravenous (IV) tramadol, a novel non-opioid product candidate for managing moderate to severe post-operative pain. In 2018, the company completed a successful initial public offering that raised $50 million.

Mission
Our mission is to develop and commercialize innovative drugs to treat patients with post-operative acute pain and other chronic pain conditions, by providing safe and effective treatments that can improve clinical outcomes.
Vision
We aim to become the partner-of-choice for patients, physicians, payers and other partners in helping to address the needs of patients with post-operative acute pain.
Key Team

Mr. David Jin (Interim CFO, COO & Corp. Sec.)

Dr. Scott A. Reines M.D., Ph.D. (Interim Chief Medical Officer)

Srinivas Subramanian (Exec. VP)

Recognition and Awards
Avenue Therapeutics has been awarded the prestigious 'Leadership in Innovation' award from the International Grains Council in 2018 and 'Most Promising New Company' by the American Pain Society in 2019.
References

https://in.investing.com/equities/avenue-therapeutics-inc

https://finance.yahoo.com/quote/ATXI/profile?p=ATXI

https://www.crunchbase.com/organization/avenue-therapeutics

https://www.avenuetx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Avenue Therapeutics
Leadership team

Dr. Lindsay Allan Rosenwald (Exec. Chairman)

Dr. Xiaoqin Lu M.D. (Consultant)

Dr. Alexandra MacLean M.D. (Chief Exec. Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
0 - 50
Headquarters
New York, New York, United States
Established
2015
Company Registration
SEC CIK number: 0001644963
Traded as
NASDAQ:ATXI
URL
https://www.avenuetx.com